Moderna Inc (MRNA)

[axelvento]

analysts at William Blair said in a note to investors that the settlement value is “better than feared,” adding that investors “were contemplating the impact of Moderna being liable for close to $5 billion.”

Such a sum, William Blair continued, would have raised concerns about the company’s liquidity. Now, however, “the company has certainty it is well funded through multiple late-stage oncology readouts” this year.

Reporting full-year earnings last month, Moderna said that it is expecting Phase 3 data for the mRNA neoantigen therapy intismeran for the adjuvant treatment of melanoma later this year.